Allergan Requests Appeal Of Del. Botox Decision

Law360, Wilmington (June 21, 2012, 10:40 PM ET) -- Allergan Inc.'s board applied on Thursday for an interlocutory appeal of a Delaware judge's game-changing decision that kept alive a shareholder derivative suit against the Botox manufacturer.

On June 11, Vice Chancellor J. Travis Laster of the Delaware Chancery Court refused to dismiss the suit, which targeted Allergan directors over alleged off-label marketing of the anti-wrinkle drug that led to a $600 million settlement with the U.S. Department of Justice.

But he did so despite a California federal court’s prior decision to throw out a parallel...
To view the full article, register now.